Bioxytran, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- David Platt
- Full Time Employees
- 3
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 233 Needham Street Newton MA United States of America 02464
- IPO Date
- Jan 5, 2010
- CIK
- 0001445815
- Website
- bioxytraninc.com
- Similar Companies
- Business
- Bioxytran, Inc. operates as a clinical-stage biopharmaceutical company focused on the development, manufacture, and commercialization of therapeutic drugs targeting viral diseases and hypoxic conditions. Its product portfolio includes ProLectin-M, a broad-spectrum oral antiviral drug designed to target galectin folds on viral spike proteins, currently in advanced clinical trials for treating mild to moderate COVID-19. The company also develops first-in-class tissue oxygenating drugs such as BXT-25 and BXT-252 for hypoxic conditions including hemorrhagic stroke and ischemia-related diseases. Bioxytran leverages proprietary co-polymer technology and patented methods to stabilize hemoglobin molecules for oxygen therapeutics aimed at reducing tissue necrosis following brain strokes and trauma. Founded in 2009 and headquartered in Boston, Massachusetts, Bioxytran operates primarily in the United States but collaborates internationally, as evidenced by clinical trial approvals from both the U.S. FDA and India's Central Drugs Standard Control Organization. Recent strategic developments include a $10 million joint venture with The Heme Foundation to develop a Universal Oxygen Carrier using GMP-quality camel hemoglobin, securing a long-term supply of a critical therapeutic ingredient. Additionally, Bioxytran secured $1.6 million in funding through a common stock purchase agreement with TRITON FUNDS to support ongoing clinical trials and working capital needs. The company has also engaged in partnerships such as a research agreement with the University of Georgia to evaluate antiviral treatments for avian influenza. Recent operational milestones comprise completion of a dose optimization clinical trial for ProLectin-M and initiation of a registrational Phase III trial for COVID-19 treatment. Bioxytran actively pursues the commercialization of its antivirals and hypoxia platforms, emphasizing groundbreaking therapies in glycovirology and tissue oxygenation to address respiratory infections, viral pandemics, and ischemic injury. The company maintains a robust patent portfolio and innovative research pipelines aimed at expanding therapeutic options in both antiviral and degenerative disease segments.
Bioxytran Highlights New Book on Real-Time Monitoring Tissue Oxygenation Relevant to Oxygen Carrier BXT-25
Bioxytran Highlights New Book on Real-Time Monitoring Tissue Oxygenation Relevant to Oxygen Carrier BXT-25
Bioxytran, Inc. (OTCMKTS:BIXT) Sees Significant Decline in Short Interest
BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT
Bioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M
Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19
Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran
Bioxytran, Inc. (OTCMKTS:BIXT) Short Interest Update
Bioxytran Conference: CEO touts broad-spectrum antiviral strategy, cites strong COVID Phase II results
Bioxytran and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics
Bioxytran (OTCMKTS:BIXT) vs. Structure Therapeutics (NASDAQ:GPCR) Head-To-Head Survey
Presenting on Emerging Growth Conference 88 Day 1 on December 10; Register to live stream
Bioxytran Announces Initiation of Coverage of its Stock by Independent Research
Bioxytran Completes Randomized Clinical Trial For its Broad-Spectrum Antiviral Drug
Bioxytran Unveils Revolutionary Precision Diagnostics on Tissue Oxygenation
Bioxytran's Breakthrough Broad-Spectrum Antiviral Technology Poised to Revolutionize Respiratory Infection Treatment
Bioxytran Secures a Source of GMP Quality Camel Hemoglobin
Bioxytran's Groundbreaking Stroke & Alzheimer's Tech Gains Validation That Measures Oxygenation Uptake During Strokes
Bioxytran's Antiviral Breakthrough Featured in University of Georgia's $100M HPAI Poultry Innovation Grand Challenge Submission
Bioxytran Completes Dose Optimization of Antiviral, ProLectin-M